Почетна › Trostruko negativni rak dojke › Masachuset
Kliničke studije za Trostruko negativni rak dojke u državi Masachuset
24 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Masachuset.
Gradovi u državi Masachuset
Zvanični tekst studije (na engleskom)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05422794A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07029399A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06150664Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07341867Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07137416The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 21. 9. 2026. · NCT05983432A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- Massachusetts General Hospital, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT07513311First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 9. 2026. · NCT06657222A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 8. 2026. · NCT06176261Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1
Узраст од 18 до 100 · Оба пола · Ажурирано 29. 7. 2026. · NCT06562192Sacituzumab Govitecan In TNBC
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- Massachusetts General Hospital - North Shore Cancer Center, Danvers
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 17. 7. 2026. · NCT04230109A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 5. 2026. · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Dana Farber Cancer Institute, Boston
- DFCI @ Foxborough, Foxborough
- DFCI @ Milford Regional Hospital, Milford
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 4. 2026. · NCT04468061This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 4. 2026. · NCT06451497Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 11. 2024. · NCT04787042Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.